Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis
- PMID: 8972038
Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis
Abstract
Dermatan sulphates have been shown to inhibit thrombus formation and thrombus growth in different experimental model of venous thrombosis. At variance with heparins, they show a remarkably low haemorrhagic potential. On the other hand, very few data are available on the effect of dermatan sulphates on arterial thrombus formation. We evaluated the effects of a low molecular weight (LMW)-dermatan sulphate, a high molecular weight (HMW)-dermatan sulphate and sulodexide (a mixture of fast-moving heparin fraction and dermatan sulphate) in comparison with LMW- and HMW-heparin, in a model of arterial thrombosis in rats. The insertion of an artificial prosthesis into the abdominal aorta of the animals induced the formation of an occluding thrombus within 2-5 days. The time in which 50% of the loops became occluded (OT50) was also calculated and used to compare the efficacy of the different drug treatments. This was 2.84 days for control animals and 4.25 and 5.80 days for HMW- and LMW-dermatan sulphate, respectively. Neither drug changed the "template" bleeding time, even at higher doses. In contrast, HMW-heparin at doses (8 mg/kg, sc, twice a day) inducing an antithrombotic activity comparable to that of dermatan sulphates, dramatically prolonged the bleeding time. LMW-heparin at the same doses was ineffective. Sulodexide (10 mg/Kg, sc, twice a day) prolonged the occlusion time to the same extent as HMW-heparin (OT50 5.10 vs. 4.14 days), with less an effect on the bleeding time (144 +/- 6 s vs. > 300 s, respectively). Histological examination confirms that the prolongation of occlusion time induced by the drugs is really related to thrombus formation inhibition at the site of arterial wall injury. Acetyl salicylic acid (ASA) (100 mg/kg/day in drinking water as lysine acetylsalicylate) did not modify the effect of Desmin 370 and Sulodexide on both occlusion and bleeding time. However, while it did not increase the antithrombotic activity of HMW-heparin, it significantly prolonged its haemorrhagic effect. In conclusion, dermatan sulphates are effective inhibitors of arterial thrombosis in rats, without inducing bleeding complications.
Similar articles
-
Pharmacological actions of sulodexide.Semin Thromb Hemost. 1998;24(2):127-38. doi: 10.1055/s-2007-995831. Semin Thromb Hemost. 1998. PMID: 9579633 Review.
-
Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit.Thromb Haemost. 1992 Dec 7;68(6):637-41. Thromb Haemost. 1992. PMID: 1287877
-
Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.Thromb Res. 2006;118(6):755-62. doi: 10.1016/j.thromres.2005.11.015. Epub 2006 Jan 10. Thromb Res. 2006. PMID: 16410020
-
Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.Thromb Haemost. 2001 Nov;86(5):1215-20. Thromb Haemost. 2001. PMID: 11816710
-
[Dermatan sulfate and the prevention of experimental venous thrombosis].Pathol Biol (Paris). 1989 Jun;37(6):759-67. Pathol Biol (Paris). 1989. PMID: 2674877 Review. French.
Cited by
-
Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.Circulation. 2015 Nov 17;132(20):1891-7. doi: 10.1161/CIRCULATIONAHA.115.016930. Epub 2015 Sep 25. Circulation. 2015. PMID: 26408273 Free PMC article. Clinical Trial.
-
Development and use of sulodexide in vascular diseases: implications for treatment.Drug Des Devel Ther. 2013 Dec 24;8:49-65. doi: 10.2147/DDDT.S6762. Drug Des Devel Ther. 2013. PMID: 24391440 Free PMC article. Review.
-
Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism.Intern Emerg Med. 2021 Mar;16(2):359-368. doi: 10.1007/s11739-020-02381-5. Epub 2020 May 25. Intern Emerg Med. 2021. PMID: 32451933 Free PMC article.
-
Alterations of fibrin network structure mediated by dermatan sulfate.J Thromb Thrombolysis. 2013 Feb;35(2):257-63. doi: 10.1007/s11239-012-0804-9. J Thromb Thrombolysis. 2013. PMID: 22987196
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical